Dr. Borghaei on the FDA Approval of Nivolumab in Small Cell Lung Cancer

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the FDA approval of nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) with disease progression following 2 or more lines of therapy.

Click to read more on the FDA approval of nivolumab for SCLC >>>

Related Content:

Fox Chase Cancer CenterOncLive TVLung Cancer
Examining 3-Year Update Data from the CASPIAN Trial
cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer